Business Description
Ambrx Biopharma Inc
NAICS : 541714
SIC : 2834
Share Class Description:
AMAM: ADRDescription
Ambrx Biopharma Inc is a clinical-stage biologics company focused on discovering and developing a novel class of engineered precision biologics (EPBs) using its proprietary expanded genetic code technology platform that allows incorporating synthetic amino acids (SAAs) into proteins within living cells. Its product pipeline includes ARX788, ARX517, ARX305 among others.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 21.34 | |||||
| Equity-to-Asset | 0.89 | |||||
| Debt-to-Equity | 0.04 | |||||
| Debt-to-EBITDA | -0.16 | |||||
| Piotroski F-Score | N/A/9 | |||||
| Altman Z-Score | 33.6 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -47.7 | |||||
| 3-Year EBITDA Growth Rate | 10.3 | |||||
| 3-Year EPS without NRI Growth Rate | 10.3 | |||||
| 3-Year FCF Growth Rate | -70.6 | |||||
| 3-Year Book Growth Rate | -10.8 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 6-1 Month Momentum % | 31.53 | |||||
| 12-1 Month Momentum % | 958.18 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 13.28 | |||||
| Quick Ratio | 13.28 | |||||
| Cash Ratio | 12.93 | |||||
| Days Sales Outstanding | 41.51 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -70.6 | |||||
| Shareholder Yield % | -8.62 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -1112.22 | |||||
| Net Margin % | -1057.92 | |||||
| FCF Margin % | -985.12 | |||||
| ROE % | -35.07 | |||||
| ROA % | -29.44 | |||||
| ROIC % | -109.71 | |||||
| 3-Year ROIIC % | -425.36 | |||||
| ROC (Joel Greenblatt) % | -504.39 | |||||
| ROCE % | -38.95 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 1400 | |||||
| PB Ratio | 48.36 | |||||
| Price-to-Tangible-Book | 18.65 | |||||
| EV-to-EBIT | -21.91 | |||||
| EV-to-EBITDA | -22.36 | |||||
| EV-to-Revenue | 276.16 | |||||
| EV-to-Forward-Revenue | 102.78 | |||||
| EV-to-FCF | -28.03 | |||||
| Price-to-Net-Current-Asset-Value | 19.8 | |||||
| Price-to-Net-Cash | 20.21 | |||||
| Earnings Yield (Greenblatt) % | -4.56 | |||||
| FCF Yield % | -3.13 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:AMAM
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Ambrx Biopharma Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 5.637 | ||
| EPS (TTM) ($) | -1.33 | ||
| Beta | 0 | ||
| Volatility % | 429.91 | ||
| 14-Day RSI | 0 | ||
| 14-Day ATR ($) | 0.84515 | ||
| 20-Day SMA ($) | 0 | ||
| 12-1 Month Momentum % | 958.18 | ||
| 52-Week Range ($) | 0.38 - 16.86 | ||
| Shares Outstanding (Mil) | 62.01 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 9999 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Ambrx Biopharma Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Ambrx Biopharma Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Ambrx Biopharma Inc Frequently Asked Questions
What is Ambrx Biopharma Inc(AMAM)'s stock price today?
The current price of AMAM is $9.70. The 52 week high of AMAM is $16.86 and 52 week low is $0.38.
When is next earnings date of Ambrx Biopharma Inc(AMAM)?
The next earnings date of Ambrx Biopharma Inc(AMAM) is 2025-05-10 Est..
Does Ambrx Biopharma Inc(AMAM) pay dividends? If so, how much?
Ambrx Biopharma Inc(AMAM) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers